Physician profile
Harminder P Singh
NPI 1497757256
$7,308.60
in general payments reported to CMS, 2019-2025
40 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $499 · 2021: $1,083 · 2022: $1,364 · 2023: $998 · 2024: $1,118 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923 · Education: $30.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.59 |
| Education | $30.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,274.92 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Fujifilm Healthcare Americas Corporation | $816.49 | 2019-2021 | |
| Pfizer INC. | $585.95 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $564.76 | 2019-2025 | Gattex, Eohilia, Entyvio |
| Janssen Biotech, INC. | $331.68 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.75 | 2020-2025 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $289.51 | 2019-2022 | |
| Celgene Corporation | $186.95 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $186.22 | 2021-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $171.16 | 2019-2023 | Rebyota, Cimzia |
| Regeneron Healthcare Solutions, INC. | $149.09 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $146.48 | 2024 | Voquezna |
| Qol Medical, LLC | $133.95 | 2021-2023 | Sucraid |
| Ardelyx, INC. | $128.19 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $126.01 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harminder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.